This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1987 Aug;14(4):858-9.

Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study

J da Costa, J A Gomes, J Espirito Santo, M Queirós

PMID: 3668998

Clinical Trial

Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study

J da Costa et al. J Rheumatol. 1987 Aug.

. 1987 Aug;14(4):858-9.

Authors

J da Costa, J A Gomes, J Espirito Santo, M Queirós

PMID: 3668998

No abstract available

PubMed Disclaimer

Similar articles

A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
Rhedda A, McCans J, Willan AR, Ford PM. Rhedda A, et al. J Rheumatol. 1985 Aug;12(4):724-7. J Rheumatol. 1985. PMID: 3903157 Clinical Trial.
A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
Kahan A, Amor B, Menkes CJ. Kahan A, et al. Ann Rheum Dis. 1985 Jan;44(1):30-3. doi: 10.1136/ard.44.1.30. Ann Rheum Dis. 1985. PMID: 3882061 Free PMC article. Clinical Trial.
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R, Shariat K, von Wilmowsky H, Böhm M. Fries R, et al. Circulation. 2005 Nov 8;112(19):2980-5. doi: 10.1161/CIRCULATIONAHA.104.523324. Circulation. 2005. PMID: 16275885 Clinical Trial.
Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
Smith CR, Rodeheffer RJ. Smith CR, et al. Am J Cardiol. 1985 Jan 25;55(3):154B-157B. doi: 10.1016/0002-9149(85)90625-3. Am J Cardiol. 1985. PMID: 3881908 Review.
Raynaud's phenomenon and systemic diseases.
Kallenberg CG. Kallenberg CG. Vasa Suppl. 1987;18:15-20. Vasa Suppl. 1987. PMID: 3299813 Review. No abstract available.

See all similar articles

Cited by

Raynaud's Phenomenon.
Coffman JD. Coffman JD. Curr Treat Options Cardiovasc Med. 2000 Jun;2(3):219-226. doi: 10.1007/s11936-000-0016-z. Curr Treat Options Cardiovasc Med. 2000. PMID: 11096527
Pathogenesis and treatment of Raynaud's phenomenon.
Coffman JD. Coffman JD. Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:45-51. doi: 10.1007/BF00053426. Cardiovasc Drugs Ther. 1990. PMID: 2285650 Review.
Calcium channel blockers for primary Raynaud's phenomenon.
Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick AL. Ennis H, et al. Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069. doi: 10.1002/14651858.CD002069.pub5. Cochrane Database Syst Rev. 2016. PMID: 26914257 Free PMC article.
[Primary and secondary Raynaud's phenomenon].
Distler JH. Distler JH. Z Rheumatol. 2008 May;67(3):211-7; quiz 218-9. doi: 10.1007/s00393-008-0282-9. Z Rheumatol. 2008. PMID: 18437399 German.
Management of Raynaud's phenomenon. Focus on newer treatments.
Roath S. Roath S. Drugs. 1989 May;37(5):700-12. doi: 10.2165/00003495-198937050-00005. Drugs. 1989. PMID: 2663416 Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information